Related Experiment Video
Updated: Aug 23, 2025
09:14
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
11.0K
Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales
David Hodgson1, Mihaly Koltai1, Fabienne Krauer1
1Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK.
Vaccine
|November 3, 2022
Summary
Nirsevimab offers a cost-effective strategy for protecting infants against Respiratory Syncytial Virus (RSV) in England and Wales. Seasonal or extended seasonal programs demonstrate potential to replace current interventions, with optimal pricing varying by strategy.
Area of Science:
- Public Health
- Health Economics
- Infectious Disease Prevention
Background:
- Respiratory Syncytial Virus (RSV) is a leading cause of infant acute lower respiratory tract infections (ALRI).
- Current protective measures for infants include limited monoclonal antibody options.
- Nirsevimab, a novel monoclonal antibody, shows promise for extended infant protection against RSV.
Purpose of the Study:
- To evaluate the cost-effectiveness of Nirsevimab intervention programs in England and Wales.
- To determine optimal Nirsevimab administration strategies and pricing for infant protection.
- To compare Nirsevimab cost-effectiveness against existing Palivizumab programs.
Main Methods:
- A dynamic transmission model for RSV was developed and calibrated using data from England and Wales.
- Various Nirsevimab administration scenarios were analyzed: year-round, seasonal, and seasonal with catch-up.
- Cost-effectiveness was assessed using an Incremental Cost-Effectiveness Ratio (ICER) threshold of £20,000/QALY.
Main Results:
- A seasonal Nirsevimab program for all infants at birth requires a price of £63/dose or less to be cost-effective compared to Palivizumab.
- An extended seasonal program with catch-up is optimal at £32/dose or less.
- Seasonal program implementation costs could reach £2 million annually before a year-round strategy becomes more optimal.
Conclusions:
- Nirsevimab demonstrates potential for cost-effective use in England and Wales for infant RSV prevention.
- Intervention strategies, particularly seasonal and extended seasonal programs, offer viable alternatives to current methods.
- Nirsevimab's cost-effectiveness extends beyond high-risk infants, suggesting broader application potential.
More Related Videos
Related Concept Videos
01:31Common Respiratory Disorders
814
Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
814
01:30Pneumonia V: Nursing management and Prevention
2.4K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.4K
01:21Acute Respiratory Failure-II
319
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
319
01:21Acute Respiratory Failure-I
287
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
287
01:29Acute Respiratory Failure-V
182
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
182
01:17Drugs Used in Lower Respiratory Disorders: Overview
552
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
552